NCT00001205 Natural History of Treated Neurocysticercosis and Long-Term Outcomes
| NCT ID | NCT00001205 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Condition | Cysticercosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 1985-10-07 |
| Primary Completion | — |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 1985-10-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Neurocysticercosis is a brain disease due to the larval stage of the pork tapeworm (Taenia solium). The most common symptoms patient experience from infection inside the substance of the brain (parenchymal disease) are seizures and headaches. When the infection is either inside the fluid pockets inside the brain (ventricular disease) or in the space around the brain (subarachnoid disease) patients can have chronic headaches, relapsing aseptic meningitis, hydrocephalus, stroke, and may require neurosurgical intervention. The purpose of this study is to treat patients with anthelmintic therapy (praziquantel and/or albendazole) and anti-inflammatories in alignment with currently accepted best practices and guidelines, depending on the neurocysticercosis subtype. The purpose of the study is to better understand and characterize clinical, biologic, and management factors during treatment that influence long term outcomes. In order to understand this further we collect patient clinical information, patient survey responses, blood, urine samples, and additional cerebral spinal fluid if already being collected for clinical care....
Eligibility Criteria
* INCLUSION CRITERIA: Arms 1-5 (NCC): 1. Aged 3 years and older. 2. Ability of participant (or legally authorized representative, LAR) to understand and the willingness to sign a written informed consent document. 3. Patients with proven or likely NCC Arm 6 (Endemic Exposures): 1. Patient with epidemiologic history compatible with possible exposure to NCC 2. Aged 18 years and older. EXCLUSION CRITERIA: Not applicable
Contact & Investigator
Elise M O'Connell, M.D.
PRINCIPAL INVESTIGATOR
National Institute of Allergy and Infectious Diseases (NIAID)
Frequently Asked Questions
Who can join the NCT00001205 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 99 Years, studying Cysticercosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00001205 currently recruiting?
Yes, NCT00001205 is actively recruiting participants. Contact the research team at perla.adamescastillo@nih.gov for enrollment information.
Where is the NCT00001205 trial being conducted?
This trial is being conducted at Bethesda, United States.
Who is sponsoring the NCT00001205 clinical trial?
NCT00001205 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). The principal investigator is Elise M O'Connell, M.D. at National Institute of Allergy and Infectious Diseases (NIAID). The trial plans to enroll 500 participants.